Log in
Enquire now
‌

US Patent 11345706 Crystalline forms of Acalabrutinib

Patent 11345706 was granted and assigned to Apotex on May, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Apotex
Apotex
Current Assignee
Apotex
Apotex
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11345706
Patent Inventor Names
Kangying Li0
Jingda Zhang0
Wancheng Guo0
Kun Cheng0
Annyt Bhattacharyya0
Bahareh Khalili0
Fabio E. S. Souza0
Date of Patent
May 31, 2022
Patent Application Number
16639668
Date Filed
August 23, 2018
Patent Primary Examiner
‌
Clinton A Brooks

The present invention provides crystalline forms of Acalabrutinib, Specific crystalline forms provided by the present invention include Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11345706 Crystalline forms of Acalabrutinib

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.